Cystagon 150 mg hard capsules

Package leaflet: Information for the user

Introduction

Package leaflet: Information for the user

CYSTAGON 50 mg Hard Capsules

CYSTAGON 150 mg Hard Capsules

cysteamine bitartrate (mercaptamine bitartrate)

Read the entire leaflet carefully before you start using this medicine, as it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, consult your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it may harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Contents of the leaflet

1. What CYSTAGON is and what it is used for

2. What you need to know before taking CYSTAGON

3. How to take CYSTAGON

4. Possible side effects

5. How to store CYSTAGON

6. Contents of the pack and other information

1. What Cystagon is and what it is used for

Cystinosis is a metabolic disease known as 'nephropathic cystinosis', which is characterized by abnormal accumulation of the amino acid cystine in various organs of the body such as the kidneys, eyes, muscles, pancreas, and brain. The accumulation of cystine causes kidney damage and excessive loss of sugar (glucose), proteins, and electrolytes. Different organs may be affected at different ages.

CYSTAGON is prescribed to treat this rare inherited disorder. CYSTAGON is a medicine that reacts with cystine, thereby reducing cystine levels within cells.

2. What you need to know before starting to take Cystagon

Do not take CYSTAGON:

• if you or your child are allergic to cysteamine bitartrate or penicillamine or to any of the other ingredients of this medicine (listed in section 6).
• if you are pregnant, especially during the first trimester.
• if you are breastfeeding.

Warnings and precautions:

• Once the diagnosis has been confirmed by leukocyte cystine measurements, treatment with CYSTAGON should be started as soon as possible.
• There have been reports of skin lesions appearing as small, hard nodules, mainly on the elbows, in children treated with high doses of various cysteamine preparations. These lesions were associated with skin striae, bone abnormalities such as fractures and bone deformities, and loose joints.

Your doctor may periodically request physical skin examinations and radiographic bone evaluations to monitor the effects of the medication. Patient or parental self-examination of the skin is recommended. If any skin or bone abnormalities appear, you must inform your doctor immediately.

• Your doctor may periodically request blood tests to monitor blood cell counts.

• CYSTAGON does not prevent the accumulation of cystine crystals in the eyes. If ophthalmic cysteamine solutions are being used for this purpose, you should continue using them.

• Unlike phosphocysteamine, another active substance similar to cysteamine bitartrate, CYSTAGON does not contain phosphate. You may be taking phosphate supplements, and your dosage may need to be adjusted if your treatment is changed from CYSTAGON to phosphocysteamine.

• Capsules should not be administered to children under approximately 6 years of age to avoid the risk of pulmonary aspiration.

• Do not ingest the desiccant container found inside the bottle.

Other medicines and CYSTAGON

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

CYSTAGON with food and drinks:

For children under six years of age, the hard capsule may be opened and its contents sprinkled onto food (e.g., milk, potatoes, or starchy foods such as cereals), or mixed into a bottle. It should not be mixed with acidic beverages such as orange juice. For complete instructions, consult your doctor.

Pregnancy

CYSTAGON must not be used during pregnancy. You should consult your doctor if you are planning to become pregnant.

Breastfeeding

CYSTAGON must not be used during breastfeeding.

Driving and use of machines:

CYSTAGON may cause drowsiness. When starting treatment, you or your child should avoid potentially hazardous activities until the effects of the medicine are well known.

3. How to take Cystagon

Follow exactly the instructions for use of this medicine given by your doctor or your child's doctor. If you have any doubts, consult your doctor again.

The dose of CYSTAGON prescribed for you or your child will depend on your or your child's weight and age.

For children up to 12 years of age, the dose will be based on body size (surface area), with the usual dose being 1.30 g/m² of body surface area per day.

For patients over 12 years of age and weighing more than 50 kg, the usual dose is 2 g/day.

In any case, the usual dose should not exceed 1.95 g/m²/day.

CYSTAGON must always be taken orally and exactly as directed by your doctor or your child's doctor. To ensure that CYSTAGON works properly, it is necessary to:

• Follow your doctor's instructions exactly. Do not increase or decrease the amount of medicine without your doctor's approval.

• Do not administer the hard capsules to children under six years of age, as they may be unable to swallow them and could choke. For children under six years of age, the hard capsule may be opened and its contents sprinkled onto food (for example, milk, potatoes, or starchy foods such as cereals), or mixed into a bottle-feed. Do not mix with acidic drinks, such as orange juice. For appropriate recommendations, consult your doctor.

• The medical treatment prescribed for you or your child will include, in addition to CYSTAGON, one or more supplements to replace important electrolytes lost by the kidneys. It is important to take or give these supplements exactly as instructed. If several doses of one of the supplements are missed, or if weakness or drowsiness is noticed, you must consult your doctor immediately.

• To determine the correct dose of CYSTAGON, periodic blood tests are required to measure the amount of cystine within the leukocytes. Your doctor or your child's doctor will determine when these blood tests should be performed. Periodic blood and urine tests are also necessary to measure the concentrations of important electrolytes in the body, so that your doctor can adjust the doses of the electrolyte supplements needed.

CYSTAGON should be taken 4 times a day, every 6 hours, preferably with meals or immediately after meals. It is important to follow the rule of taking the dose every six hours as strictly as possible.

Treatment with CYSTAGON should be continued indefinitely, as directed by your doctor.

To open and close the Cystagon bottle easily, follow the instructions included below:

Instructions for opening and closing the container

If you use more CYSTAGON than you should

If you have taken more medicine than prescribed, or if drowsiness occurs, consult your doctor or your child's doctor immediately, or go to a hospital emergency department.

If you forget to take CYSTAGON

If you forget to take a dose of the medicine, take it as soon as possible. However, if less than 2 hours remain before the next dose, skip the missed dose and return to your regular dosing schedule. Do not take a double dose to make up for forgotten doses.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone experiences them.

CYSTAGON may cause drowsiness or reduced alertness compared to the normal state in some people. Make sure you know how you or your child reacts to this medicine before engaging in any activity that could be dangerous if you are not fully alert.

The following adverse effects have been reported in the following frequency categories: very common (occurs in at least 1 in 10 patients), common (occurs in at least 1 in 100 patients), uncommon (occurs in at least 1 in 1,000 patients), rare (occurs in at least 1 in 10,000 patients), very rare (occurs in at least 1 in 100,000 patients).

• Very common: vomiting, nausea, diarrhoea, loss of appetite, fever, and drowsiness.

• Common: abdominal pain or discomfort, bad breath and unpleasant body odour, skin rash, gastroenteritis, fatigue, headache, encephalopathy (brain disorder), and abnormal liver function tests.

• Uncommon: skin striae, skin lesions (small hard lumps on elbows), loose joints, leg pain, bone fractures, scoliosis (spinal curvature), bone deformities and fragility, hair depigmentation, severe allergic reaction, somnolence, seizures, nervousness, hallucinations, decreased number of white blood cells, gastrointestinal ulcer with secondary gastrointestinal bleeding, and renal disorders manifested by swelling of the extremities and weight gain.

Since some of these adverse effects are serious, ask your doctor or paediatrician to explain the warning signs to you.

Reporting of adverse effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Cystagon Storage

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date is the last day of the month indicated.

Do not store above 25°C.

Keep the container tightly closed to protect it from light and moisture.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of containers and medicines you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of CYSTAGON

• The active substance is cisteamine bitartrate (mercaptamine bitartrate). Each CYSTAGON 50 mg hard capsule contains 50 mg of cisteamine (as mercaptamine bitartrate). Each CYSTAGON 150 mg hard capsule contains 150 mg of cisteamine (as mercaptamine bitartrate).

• The other components are microcrystalline cellulose, pregelatinized starch, magnesium stearate/sodium lauryl sulfate, colloidal silicon dioxide, sodium croscarmellose. Capsule shell components: gelatin, titanium dioxide, black ink on hard capsules (E172).

Appearance of the product and contents of the pack

Hard capsules

• Cystagon 50 mg: White, opaque hard capsules with the inscriptions "CYSTA 50" on the body and "RECORDATI RARE DISEASES" on the cap.

Bottles containing 100 or 500 hard capsules. Only certain pack sizes may be marketed.

• Cystagon 150 mg: White, opaque hard capsules with the inscriptions "CYSTAGON 150" on the body and "RECORDATI RARE DISEASES" on the cap.

Bottles containing 100 or 500 hard capsules. Only certain pack sizes may be marketed.

Marketing Authorization Holder

Recordati Rare Diseases
Tour Hekla 52, Avenue du Général de Gaulle
F-92800 Puteaux
France

Manufacturer

Recordati Rare Diseases
Tour Hekla 52, Avenue du Général de Gaulle
F-92800 Puteaux
France

or

Recordati Rare Diseases
Eco River Parc
30, rue des Peupliers
F-92000 Nanterre
France

Further information on this medicinal product is available upon request by contacting the local representative of the Marketing Authorization Holder.

Date of the most recent review of this leaflet:

Detailed information on this medicine is available on the website of the European Medicines Agency: https://www.ema.europa.eu/. There are also links to other websites on rare diseases and orphan medicines.